MAPT and Alzheimer disease: A study aggregating results from two Phase II Clinical trials that have used 18F -flortaucipir PET scans in a total of 364 study participants showed that tau PET provides valuable prognostic information in terms of clinical deterioration over 18 months in MCI and AD [196].